Head to head · SEC data as of July 10, 2026
Eli Lilly
92
Quality score · out of 100
AbbVie
49
Quality score · out of 100
Eli Lilly comes in ahead: a quality score of 92 versus 49 for AbbVie. Eli Lilly wins on net margin (35% vs 5.8%), revenue growth (22.9% vs 6.2%) and earnings growth (31.1% vs -5.4%). AbbVie answers with cash generation (FCF) (31.8% vs 16.4%).
| Metric | Eli Lilly | AbbVie |
|---|---|---|
| Quality score (0-100) | 92 | 49 |
| Net margin | 35% | 5.8% |
| Gross margin | — | — |
| ROE | 81% | — |
| Net debt/EBITDA | — | 3.42× |
| FCF margin | 16.4% | 31.8% |
| Revenue growth (annualized) | 22.9% | 6.2% |
| Earnings growth (annualized) | 31.1% | -5.4% |
TTM metrics with official SEC data, refreshed daily. Bold green marks the winner of each metric. A dash means the metric doesn't apply or isn't reliable.
Eli Lilly. Eli Lilly is one of the world's largest pharmaceutical companies. It researches, develops and sells medicines; in recent years its growth leans heavily on its treatments for diabetes and obesity.
AbbVie. AbbVie is a large U.S. pharmaceutical company. For years it relied on a single blockbuster drug (Humira); today its challenge is to grow with its new generation of medicines, especially in immunology and aesthetics.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
What this comparison doesn't tell you
The score measures business quality, not whether the stock is cheap or expensive: the better company can be the worse investment if you overpay. For the valuation verdict, enter each one's current price in the analyzer:
Who has the stronger fundamentals today, Eli Lilly or AbbVie?
By the StockSemáforo model (profitability, growth and financial strength, built on official SEC data), Eli Lilly scores higher: 92 versus 49 out of 100. The score is recomputed nightly with the latest filings.
Does that make Eli Lilly the better investment?
No. The score measures business quality, not valuation: an excellent company can trade at an excessive price and be a poor investment at that price. To find out whether it's cheap or expensive, enter its current quote in the StockSemáforo analyzer.
Other comparisons
Pfizer vs Merck · Johnson & Johnson vs Pfizer · Amgen vs Gilead · UnitedHealth vs CVS Health · See all comparisons →